Neonatal Sepsis Management
Customize your policy alerts
Sign up for Arizona Complete Health Policy CP.MP.85 alerts
Get alerted when Policy CP.MP.85 changes without checking for updates manually.
Monitor payer policy activity
Clinical criteria and levels of care for identification, initial treatment, disposition, and discharge planning for neonates with suspected or proven sepsis; applies to providers caring for newborns in Health Plans affiliated with Centene Corporation (Arizona Complete Health).
No material clinical or coverage changes in this revision.
Coverage Criteria — Neonatal Sepsis Management
Level of care and antibiotic-duration based placement
Covered when ALL of the following are met for the specified episode/day and clinical condition
Supports placement at Level II
All three subcriteria required
Consider transitional care if home antibiotics unsafe
Continuation of level III if criteria persist
Transition to lower level once culture/sensitivity known and infant medically stable
Discharge with or without home antibiotics
Discharge criteria — covered when ALL of the following are met
Required
Required
Required
Required for home IV antibiotics
Required
Evaluation, testing, and empiric therapy
Clinical evaluation and testing considerations
Management differs by gestational age
Meningitis without bacteremia is rare but more common in preterm infants
Procalcitonin and other labs are imperfect predictors
If a cesarean delivery is performed before onset of labor and the birthing individual's amniotic membranes are intact, intrapartum GBS prophylaxis need not be given. For all other birthing individuals (including those with positive vaginal‑rectal cultures at the time of labor or rupture of membranes), intrapartum antibiotic prophylaxis should be administered per obstetric guidance.
Coverage under this clinical policy is subject to the terms, conditions, exclusions, and limitations of the member's coverage documents (for example, evidence of coverage, certificate of coverage, policy, or contract). When state Medicaid provisions conflict with this policy, the state Medicaid provisions take precedence. Providers should verify applicable plan requirements and prior authorization procedures before delivery of services.
When blood cultures remain sterile, antibiotic therapy should be discontinued by 36 to 48 hours of incubation unless there is clear evidence of a site‑specific infection that justifies continued treatment. Routine continuation of empiric antibiotics beyond this observation period is not indicated without documented clinical or microbiologic evidence.
Coding and Billing References
| rev code 171 | Level I nursery / transitional care |
| rev code 172 | Level II nursery |
| rev code 173 | Level III nursery |
| rev code 172 | Level II nursery |
| rev code 173 | Level III nursery |
| rev code 171 | Level I nursery / transitional care |
Provider Actions, Authorization & Documentation
Prior Authorization per Plan
Prior authorization requirements vary by member plan. Determine and obtain any required prior authorization from the Health Plan before admission or continuation of inpatient nursery care when applicable.
- Check the member's coverage documents and plan prior authorization rules
- Contact the Health Plan's prior authorization department for plan-specific requirements
Medical Necessity & Level of Care
Medical necessity for management of neonatal sepsis is tied to the specified levels of care and revenue codes. Assign the appropriate care level based on clinical status and the policy criteria to support medical necessity determinations.
- Level I (rev code 171): transitional care or level I when antibiotics are the only intervention and outpatient antibiotics are inappropriate
- Level II (rev code 172): asymptomatic or well-appearing infants on up to 48 hours of antibiotics pending culture results
- Level III (rev code 173): symptomatic infants meeting sepsis signs/temperature criteria and on antibiotics
Coverage Conditional on Plan Documents
Coverage is conditional on the member's coverage documents, applicable state and federal requirements, and Health Plan administrative policies. This clinical policy is guidance and does not guarantee payment.
- Follow the member's evidence of coverage, certificate of coverage, policy, or contract of insurance for payment rules
- State and federal requirements and Health Plan-level policies may modify applicability
Discharge Documentation Requirements
Discharge requires documentation that the infant is clinically stable and that the home situation and caregivers are appropriate and agree to the plan of care. If discharged with antibiotics, specific discharge arrangements and follow-up must be documented.
- Document clinical stability prior to discharge
- Document assessment of home situation and caregiver agreement
- If going home with antibiotics: documented contractual arrangement with a qualified home infusion provider, secure IV access if applicable, contact information for responsible physician and backup facility provided, and follow-up scheduled within 48 hours
Antibiotic Observation & Continuation
Antibiotic observation and continuation should be clearly documented. Typical observation is 36–48 hours pending blood culture results; continuation of antibiotics beyond this period requires documentation of clinical indications and rationale for ongoing inpatient care.
- Document start and planned duration of antibiotics (typically 36–48 hours for rule-out sepsis)
- If cultures are negative and antibiotics are to continue beyond 48 hours, document why outpatient therapy is inappropriate or why continued inpatient/transitional care is required
- When cultures are positive, document treatment plan and level-of-care rationale
Background and Epidemiology
Group B streptococcus (GBS) is the leading cause of early‑onset neonatal sepsis. Early‑onset disease is defined as culture‑proven infection within the first six days of life. Intrapartum antibiotic prophylaxis for colonized or at‑risk birthing individuals has reduced the incidence of early‑onset GBS disease, but careful risk assessment, timely empiric therapy for symptomatic infants, and appropriate duration of antibiotics remain central to neonatal management.
Definitions — Early- and Late-onset GBS Disease
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.